CLIMB BIO, INC. Research and Development Expense
CLIMB BIO, INC. (CLYM) reported Research and Development Expense of $9.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- CLIMB BIO, INC. research and development expense for the quarter ending 2026-06-30 was $9.71M, a 47.74% increase year-over-year.
- CLIMB BIO, INC. research and development expense for the quarter ending 2026-03-31 was $9.37M, a 45.91% decline year-over-year.
- CLIMB BIO, INC. research and development expense for the quarter ending 2025-12-31 was $13.74M, a 130.54% increase year-over-year.
- CLIMB BIO, INC. research and development expense for the quarter ending 2025-09-30 was $9.07M, a 45.40% increase year-over-year.
- CLIMB BIO, INC. research and development expense for fiscal 2025 was $46.71M, a 225.84% increase from fiscal 2024.
- CLIMB BIO, INC. research and development expense for fiscal 2024 was $14.34M, a 6.98% decline from fiscal 2023.
- CLIMB BIO, INC. research and development expense for fiscal 2023 was $15.41M, a 41.21% decline from fiscal 2022.
- CLIMB BIO, INC. research and development expense for fiscal 2022 was $26.21M, a 12.40% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.71M 10-Q · filed 2026-08-06 | $19.09M 10-Q · filed 2026-08-06 | $32.83M derived: sum of 3 quarters · filed 2026-08-06 | $41.90M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $9.37M 10-Q · filed 2026-05-07 | $23.11M derived: sum of 2 quarters · filed 2026-05-07 | $32.18M derived: sum of 3 quarters · filed 2026-05-07 | $38.76M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $22.81M derived: sum of 2 quarters · filed 2026-03-05 | $29.39M derived: sum of 3 quarters · filed 2026-08-06 | $46.71M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $9.07M 10-Q · filed 2025-11-06 | $15.65M derived: sum of 2 quarters · filed 2026-08-06 | $32.98M 10-Q · filed 2025-11-06 | $38.93M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $6.58M 10-Q · filed 2026-08-06 | $23.90M 10-Q · filed 2026-08-06 | $29.86M derived: sum of 3 quarters · filed 2026-08-06 | $36.10M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $17.33M 10-Q · filed 2026-05-07 | $23.29M derived: sum of 2 quarters · filed 2026-05-07 | $29.53M derived: sum of 3 quarters · filed 2026-05-07 | $30.57M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $12.20M derived: sum of 2 quarters · filed 2026-03-05 | $13.24M derived: sum of 3 quarters · filed 2026-03-05 | $14.34M 10-K · filed 2026-03-05 | $14.18M 10-K · filed 2025-03-25 | |||
| 2024-09-30 | $6.24M 10-Q · filed 2025-11-06 | $6.09M 10-Q · filed 2024-11-12 | $7.29M derived: sum of 2 quarters · filed 2025-11-06 | $8.38M 10-Q · filed 2025-11-06 | $8.22M 10-Q · filed 2024-11-12 | $11.50M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $1.05M 10-Q · filed 2025-08-12 | $2.14M 10-Q · filed 2025-08-12 | $5.26M derived: sum of 3 quarters · filed 2025-08-12 | $8.14M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $1.09M 10-Q · filed 2025-05-14 | $4.22M derived: sum of 2 quarters · filed 2025-05-14 | $7.09M derived: sum of 3 quarters · filed 2025-05-14 | $10.78M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $6.00M derived: sum of 2 quarters · filed 2025-03-25 | $9.69M derived: sum of 3 quarters · filed 2025-03-25 | $15.41M 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | $2.88M 10-Q · filed 2024-11-12 | $6.56M derived: sum of 2 quarters · filed 2024-11-12 | $12.28M 10-Q · filed 2024-11-12 | $17.21M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $3.69M 10-Q · filed 2024-08-14 | $9.41M 10-Q · filed 2024-08-14 | $14.34M derived: sum of 3 quarters · filed 2024-08-14 | $18.59M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $5.72M 10-Q · filed 2024-05-15 | $10.65M derived: sum of 2 quarters · filed 2024-05-15 | $14.90M derived: sum of 3 quarters · filed 2024-05-15 | $23.67M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $9.19M derived: sum of 2 quarters · filed 2024-03-28 | $17.95M derived: sum of 3 quarters · filed 2024-03-28 | $26.21M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $4.26M 10-Q · filed 2023-11-14 | $13.03M derived: sum of 2 quarters · filed 2023-11-14 | $21.29M 10-Q · filed 2023-11-14 | $28.17M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $8.77M 10-Q · filed 2023-08-10 | $8.74M 10-Q · filed 2022-08-15 | $17.03M 10-Q · filed 2023-08-10 | $16.85M 10-Q · filed 2022-08-15 | $23.91M derived: sum of 3 quarters · filed 2023-08-10 | $29.90M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $8.26M 10-Q · filed 2023-05-11 | $8.11M 10-Q · filed 2022-05-16 | $15.14M derived: sum of 2 quarters · filed 2023-05-11 | $21.13M derived: sum of 3 quarters · filed 2023-05-11 | $26.61M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $6.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $12.87M derived: sum of 2 quarters · filed 2023-03-06 | $18.35M derived: sum of 3 quarters · filed 2023-03-06 | $23.32M 10-K · filed 2023-03-06 | $22.05M 10-K · filed 2022-03-07 | |||
| 2021-09-30 | $5.99M 10-Q · filed 2022-11-14 | $5.70M 10-Q · filed 2021-11-08 | $11.47M derived: sum of 2 quarters · filed 2022-11-14 | $16.44M 10-Q · filed 2022-11-14 | $15.46M 10-Q · filed 2021-11-08 | $19.86M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $5.48M 10-Q · filed 2022-08-15 | $9.75M 10-Q · filed 2022-08-15 | $13.88M derived: sum of 3 quarters · filed 2022-08-15 | $15.81M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $4.27M 10-Q · filed 2022-05-16 | $8.40M derived: sum of 2 quarters · filed 2022-05-16 | $10.33M derived: sum of 3 quarters · filed 2022-05-16 | $11.65M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $6.05M derived: sum of 2 quarters · filed 2022-03-07 | $7.38M derived: sum of 3 quarters · filed 2022-03-07 | $8.77M 10-K · filed 2022-03-07 | ||||
| 2020-09-30 | $1.93M 10-Q · filed 2021-11-08 | $3.25M derived: sum of 2 quarters · filed 2021-11-08 | $4.64M 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | $1.32M 10-Q · filed 2021-09-13 | $2.71M 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |